^
    Apply
    A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation (NCT04973163)
    Phase 1
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    04/17/2024
    Initiation :
    08/03/2021
    Primary completion :
    11/29/2024
    Completion :
    12/27/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    BI 1823911 • BI 1701963 • midazolam hydrochloride